Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity.

Nelson N, Lopez-Pelaez M, Palazon A, Poon E, De La Roche M, Barry S, Valge-Archer V, Wilkinson RW, Dovedi SJ, Smith PD.

Oncoimmunology. 2019 Apr 26;8(8):1599635. doi: 10.1080/2162402X.2019.1599635. eCollection 2019.

2.

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.

Van den Eynde M, Mlecnik B, Bindea G, Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F, Angelova M, Vasaturo A, Bruni D, Jouret-Mourin A, Baldin P, Huyghe N, Haustermans K, Debucquoy A, Van Cutsem E, Gigot JF, Hubert C, Kartheuser A, Remue C, Léonard D, Valge-Archer V, Pagès F, Machiels JP, Galon J.

Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3. doi: 10.1016/j.ccell.2018.11.003.

PMID:
30537506
3.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pagès F, Machiels JP, Galon J.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx123. Erratum in: J Natl Cancer Inst. 2018 Apr 1;110(4):438.

PMID:
28922789
4.

MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.

Ghadially H, Brown L, Lloyd C, Lewis L, Lewis A, Dillon J, Sainson R, Jovanovic J, Tigue NJ, Bannister D, Bamber L, Valge-Archer V, Wilkinson RW.

Br J Cancer. 2017 Apr 25;116(9):1208-1217. doi: 10.1038/bjc.2017.79. Epub 2017 Mar 23.

5.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.

Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW.

Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6.

6.

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, González-Muñoz A, Parmentier J, Black C, Soden J, Freeth J, Jovanović J, Leyland R, Al-Lamki RS, Leishman AJ, Rust SJ, Stewart R, Jermutus L, Bradley JR, Bedian V, Valge-Archer V, Minter R, Wilkinson RW.

Oncotarget. 2016 Oct 18;7(42):68278-68291. doi: 10.18632/oncotarget.11943.

7.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboüe R, Frebourg T, Pagès F, Valge-Archer V, Latouche JB, Galon J.

Immunity. 2016 Mar 15;44(3):698-711. doi: 10.1016/j.immuni.2016.02.025.

8.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pagès F, Valge-Archer V, Galon J.

Sci Transl Med. 2016 Feb 24;8(327):327ra26. doi: 10.1126/scitranslmed.aad6352.

PMID:
26912905
9.

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.

Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW.

Oncoimmunology. 2015 Jun 1;4(12):e1051922. eCollection 2015 Dec.

10.

Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients.

Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, Waldner M, Berger A, Fridman WH, Rafii A, Valge-Archer V, Pagès F, Speicher MR, Galon J.

Sci Transl Med. 2014 Mar 19;6(228):228ra37. doi: 10.1126/scitranslmed.3007240.

11.

In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.

Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L, Andreyeva T, Lowe D, Lane S, Thom G, Valge-Archer V, Gill D, Young D, Bloom L.

MAbs. 2010 May-Jun;2(3):335-46. Epub 2010 May 23.

12.

Development trends for monoclonal antibody cancer therapeutics.

Reichert JM, Valge-Archer VE.

Nat Rev Drug Discov. 2007 May;6(5):349-56. Review.

PMID:
17431406
13.

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, Collins M, Carreno BM.

J Immunol. 2003 Jan 15;170(2):711-8.

14.
15.

Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.

Rabbitts TH, Axelson H, Forster A, Grutz G, Lavenir I, Larson R, Osada H, Valge-Archer V, Wadman I, Warren A.

Leukemia. 1997 Apr;11 Suppl 3:271-2.

PMID:
9209362
16.

The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.

Valge-Archer VE, Osada H, Warren AJ, Forster A, Li J, Baer R, Rabbitts TH.

Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8617-21.

17.

Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.

McCaffrey PG, Kim PK, Valge-Archer VE, Sen R, Rao A.

Nucleic Acids Res. 1994 Jun 11;22(11):2134-42.

18.

Nuclear factor of activated T cells contains Fos and Jun.

Jain J, McCaffrey PG, Valge-Archer VE, Rao A.

Nature. 1992 Apr 30;356(6372):801-4.

PMID:
1533441
20.

Analysis of the AP-1 sites in the IL-2 promoter.

Jain J, Valge-Archer VE, Rao A.

J Immunol. 1992 Feb 15;148(4):1240-50.

PMID:
1737937
21.

Transformation of T lymphocytes by the v-fos oncogene.

Valge-Archer VE, de Villiers J, Sinskey AJ, Rao A.

J Immunol. 1990 Dec 15;145(12):4355-64.

PMID:
2124241

Supplemental Content

Loading ...
Support Center